Home  |  Contact

Cellosaurus RT4rCDDP1000 (CVCL_RR19)

[Text version]

Cell line name RT4rCDDP1000
Accession CVCL_RR19
Resource Identification Initiative To cite this cell line use: RT4rCDDP1000 (RRID:CVCL_RR19)
Comments Part of: Resistant Cancer Cell Line (RCCL) collection.
Doubling time: 39.6 hours (PubMed=26055179).
Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP).
Sequence variations FGFR3-TACC3 gene fusion (from parent cell line).
Homozygous for CDKN2A deletion (from parent cell line).
TERT c.228C>T (-124C>T); in promoter (from parent cell line).
Disease Bladder carcinoma (NCIt: C4912)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Parent: CVCL_0036 (RT-4)
Sex of cell Male
Age at sampling 63Y
Category Cancer cell line
Web pages http://www.wass-michaelislab.org/rccl.php

PubMed=26055179; DOI=10.1016/j.tranon.2015.04.002
Vallo S., Michaelis M., Rothweiler F., Bartsch G., Gust K.M., Limbart D.M., Rodel F., Wezel F., Haferkamp A., Cinatl J. Jr.
Drug-resistant urothelial cancer cell lines display diverse sensitivity profiles to potential second-line therapeutics.
Transl. Oncol. 8:210-216(2015)

Other Wikidata; Q54951365
Entry history
Entry creation05-Mar-2018
Last entry updated05-Jul-2019
Version number3